{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GBM&page=6", "query": { "condition": "GBM", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 1360, "total_pages": 136, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GBM&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GBM&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T09:08:23.460Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02055196", "title": "Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Oligodendroglioma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Tumor" ], "interventions": [ { "name": "carboxylesterase-expressing allogeneic neural stem cells", "type": "BIOLOGICAL" }, { "name": "irinotecan hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 0, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2014-06-02", "last_synced_at": "2026-10-22T09:08:23.460Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02055196" }, { "nct_id": "NCT00002754", "title": "Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Melanoma (Skin)", "Metastatic Cancer" ], "interventions": [ { "name": "monoclonal antibody Me1-14 F(ab')2", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 6, "start_date": "1993-02", "completion_date": "2001-04", "has_results": false, "last_update_posted_date": "2013-02-20", "last_synced_at": "2026-10-22T09:08:23.460Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002754" }, { "nct_id": "NCT02272270", "title": "Phase I Newly Diagnosed GBM With Temozolomide, Radiation, and Minocycline Followed by Adjuvant Minocycline/Temozolomide (D-TERMINED)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Newly Diagnosed High Grade Glioma" ], "interventions": [ { "name": "Minocycline with chemoradiation (temozolomide and radiation therapy)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2014-10-27", "completion_date": "2018-02-18", "has_results": false, "last_update_posted_date": "2019-06-19", "last_synced_at": "2026-10-22T09:08:23.460Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT02272270" }, { "nct_id": "NCT04049669", "title": "Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Medulloblastoma", "Ependymoma", "Diffuse Intrinsic Pontine Glioma" ], "interventions": [ { "name": "Indoximod", "type": "DRUG" }, { "name": "Partial Radiation", "type": "RADIATION" }, { "name": "Full-dose Radiation", "type": "RADIATION" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Theodore S. Johnson", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "3 Years to 21 Years" }, "enrollment_count": 130, "start_date": "2019-10-02", "completion_date": "2027-10-02", "has_results": false, "last_update_posted_date": "2026-01-08", "last_synced_at": "2026-10-22T09:08:23.460Z", "location_count": 5, "location_summary": "Augusta, Georgia • Druid Hills, Georgia • Boston, Massachusetts + 2 more", "locations": [ { "city": "Augusta", "state": "Georgia" }, { "city": "Druid Hills", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04049669" }, { "nct_id": "NCT04471844", "title": "Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Glioblastoma Multiforme" ], "interventions": [ { "name": "Optune®", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "NovoCure Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 981, "start_date": "2020-12-08", "completion_date": "2026-02-19", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-22T09:08:23.460Z", "location_count": 86, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04471844" }, { "nct_id": "NCT02015819", "title": "Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Oligodendroglioma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Recurrent Adult Brain Tumor", "Anaplastic Oligoastrocytoma" ], "interventions": [ { "name": "E. coli CD-expressing genetically modified neural stem cells", "type": "BIOLOGICAL" }, { "name": "flucytosine", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2014-10-07", "completion_date": "2017-10-07", "has_results": true, "last_update_posted_date": "2021-10-20", "last_synced_at": "2026-10-22T09:08:23.460Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02015819" }, { "nct_id": "NCT00005637", "title": "Combination Chemotherapy Following Radiation Therapy in Treating Patients With Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "carmustine", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-12", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2013-04-04", "last_synced_at": "2026-10-22T09:08:23.460Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005637" }, { "nct_id": "NCT02711137", "title": "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB057643", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2016-05-18", "completion_date": "2019-02-13", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-10-22T09:08:23.460Z", "location_count": 16, "location_summary": "Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02711137" }, { "nct_id": "NCT00024570", "title": "Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Glioma", "Glioblastoma Multiforme", "Anaplastic Astrocytoma", "Mixed Oligoastrocytoma" ], "interventions": [ { "name": "IL13-PE38QQR", "type": "DRUG" }, { "name": "targeted fusion protein therapy", "type": "PROCEDURE" }, { "name": "surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2000-11", "completion_date": "2007-07", "has_results": false, "last_update_posted_date": "2014-11-14", "last_synced_at": "2026-10-22T09:08:23.460Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024570" }, { "nct_id": "NCT01445691", "title": "More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Benign Neoplasms, Brain", "Brain Cancer", "Brain Neoplasms, Benign", "Brain Neoplasms, Malignant", "Brain Tumor, Primary", "Brain Tumor, Recurrent", "Brain Tumors", "Intracranial Neoplasms", "Neoplasms, Brain", "Neoplasms, Intracranial", "Primary Brain Neoplasms", "Primary Malignant Brain Neoplasms", "Primary Malignant Brain Tumors", "Gliomas", "Glioblastoma" ], "interventions": [ { "name": "5-ALA (Gliolan)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Constantinos Hadjipanayis", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 0, "start_date": "2015-11", "completion_date": "2016-09", "has_results": false, "last_update_posted_date": "2016-05-17", "last_synced_at": "2026-10-22T09:08:23.460Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Ann Arbor, Michigan • Detroit, Michigan + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01445691" } ] }